Compare Archer-Daniels-Midland Co (ADM) vs Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Archer-Daniels-Midland Co vs Bio-Rad Laboratories, Inc. Class A Common Stock — how do they compare? Archer-Daniels-Midland Co trades at $80.16 (market cap $37.69B), while Bio-Rad Laboratories, Inc. Class A Common Stock trades at $283.5 (market cap $7.85B). The key difference: Archer-Daniels-Midland Co is far larger — about 4.8× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Archer-Daniels-Midland Co pays a 2.66% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| ADM | BIO | |
|---|---|---|
Market Cap | $37.69B | $7.85B |
Sector | Consumer Staples | Health |
52-Week High | $84.11 | $339.75 |
52-Week Low | $53.54 | $241.71 |
Enterprise Value | $47.72B | $7.66B |
Dividend Yield | 2.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADM trades at $78.20, up 1.84% recently, with a bullish technical signal from moving averages and a consensus analyst price target of $78.00. The company has beaten EPS estimates for three consecutive quarters, though revenue has declined from $101.6B in 2022 to $80.3B in 2025. Net cash flow improved to $1.58B in 2025, reversing negative trends from prior years, while the stock shows a P/E of 34.79 and P/S of 0.47, indicating mixed valuation signals.
Outlook is cautiously optimistic with strong cash flow and earnings beats, but risks include declining revenue margins and competitive pressures. The stock offers value characteristics with a low P/S ratio, yet investors face headwinds from narrowing profit margins and global trade volatility in agricultural markets.
BIO trades at $292.50, down 1.47% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported revenue of $2.58B for 2025 with net income of $759.90M, though it missed EPS estimates for three consecutive quarters. Positive cash flow from operations of $532.20M supports financial health, while recent news highlights Nasdaq compliance and industry participation.
Outlook remains cautiously optimistic with a consensus price target of $305.00, representing ~4% upside. Risks include consistent earnings misses and high P/E of 49.11, but strong analyst buy sentiment (53.85%) and improving profitability margins offer potential for recovery if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Archer-Daniels-Midland Co
Archer-Daniels Midland is a major processor of oilseeds, corn, wheat, and other agricultural commodities. Additionally, the company owns an extensive network of logistical assets to store and transport crops around the globe. ADM also runs a nutrition business that focuses on both human and animal ingredients. The company is also a large producer of corn-based sweeteners, starches, and ethanol.
Read more on ADM →About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →
